Global Gigantism Drugs Market, By Drug Class (Growth Hormone Inhibitors, Dopamine Agonist, Others), Drug Type (Generic, Branded), End-Users (Hospitals, Specialty Clinics, Home Healthcare, Others), Distribution Channel (Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others), Country (U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa) Industry Trends and Forecast to 2028
Market Analysis and Insights: Global Gigantism Drugs Market
Global gigantism drugs market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market is growing at a healthy CAGR in the above-mentioned research forecast period. Emerging markets and huge investments in research and development are the factors responsible for the growth of this market.
However, technological advancement in treatment and diagnosis and rising genetic inherited disorders also boost up the market growth. Moreover, increasing demand for treatment and rising patient awareness about different treatment options, increasing medical tourism in developing countries and rising investment by market players also generate market opportunities. But adverse effects related to the treatment and low prevalence rate may hamper the global gigantism drugs market.
Gigantism is a rare disorder characterized by abnormal growth in children. The changes were most prominently seen in children in terms of height as well as girth. Gigantism occurs when the child's pituitary gland produces too much growth hormone, which is also known as somatotropin. A pituitary gland tumour is almost always the cause of gigantism. There are other common causes of gigantism are McCune (Albright Syndrome), Carney complex, Multiple endocrine neoplasia type 1 (MEN1), neurofibromatosis, and others.
Gigantism is extremely rare, till the date only 100 to 200 cases were reported. The prevalence is around 36 to 70 cases per million and the incidence rate is 3 to 4 per million and cases per year.
This gigantism drugs market provides details of market share, new developments and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
Global Gigantism Drugs Market Scope and Market Size
The gigantism drugs market is segmented on the basis of drug class, drug type, end-users and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of drug class, the gigantism drugs market is segmented into growth hormone inhibitors, dopamine agonist and others. The growth hormone inhibitors further divided into octreotide, lanreotide and others. Dopamine agonist further divided into bromocriptine, cabergoline and others.
- On the basis of drug type, the gigantism drugs market is segmented into branded and generic. Branded type further divided into Somavert, Sandostatin, Bynfezia Pen, Somatuline Depot and others.
- On the basis of end-users, the gigantism drugs market is segmented into hospitals, specialty clinics and others.
- On the basis of distribution channel, the gigantism drugs market has also been segmented into direct tender, hospital pharmacy, retail pharmacy, online pharmacy and others.
Gigantism Drugs Market Country Level Analysis
Gigantism drugs market is analysed and market size information is provided by country, drug class, drug type, end-users and distribution channel as referenced above.
The countries covered in the gigantism drugs market report are U.S., Canada, Mexico in North America, Brazil, Argentina, Peru, Rest of South America, as part of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa, as a part of Middle East and Africa.
On geographical estimation, North America accounts the largest market share due to the presence of high healthcare expenditure and research and development. Europe accounts the second largest market share due to presence of refined medical facilities. Asia-Pacific is expected to account for the largest market share over coming years for the Gigantism Drugs market due to increased advancement in the technology as well as growing healthcare expenditure.
The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Patient Epidemiology Analysis
Gigantism drugs market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Competitive Landscape and Gigantism Drugs Market Share Analysis
Gigantism drugs market competitive landscape provides details by competitor details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to gigantism drugs market.
The major players covered in the gigantism drugs market are Pfizer Inc. Novartis AG, Fresenius Kabi USA, Mylan N.V., Sagent Pharmaceuticals, Inc., Hikma Pharmaceuticals PLC, Ipsen Pharma, Sun Pharmaceutical Industries Limited., Chiasma, Inc., Teva Pharmaceuticals Industries Ltd, Ingenus Pharmaceutical, Zydus Pharmaceutical USA, VeroScience, among other domestic and global players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
SKU-
